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The newly emergedMiddle East respiratory syndrome coronavirus (MERS-CoV) has infected at least 77 people, with a fatality
rate of more than 50%. Alarmingly, the virus demonstrates the capability of human-to-human transmission, raising the possibil-
ity of global spread and endangering world health and economy. Here we have identified the receptor-binding domain (RBD)
from theMERS-CoV spike protein and determined its crystal structure. This study also presents a structural comparison of
MERS-CoV RBDwith other coronavirus RBDs, successfully positioningMERS-CoV on the landscape of coronavirus evolution
and providing insights into receptor binding byMERS-CoV. Furthermore, we found that MERS-CoV RBD functions as an effec-
tive entry inhibitor of MERS-CoV. The identifiedMERS-CoV RBDmay also serve as a potential candidate for MERS-CoV sub-
unit vaccines. Overall, this study enhances our understanding of the evolution of coronavirus RBDs, provides insights into re-
ceptor recognition byMERS-CoV, andmay help control the transmission of MERS-CoV in humans.
Since the summer of 2012, a novel coronavirus, Middle Eastrespiratory syndrome coronavirus (MERS-CoV), has emerged
from the Middle East and spread to parts of Europe. MERS-CoV
infection often leads to acute pneumonia and renal failure, and the
human fatality rate is more than 50% (1, 2). To date, MERS-CoV
has infected at least 77 people and was able to be transmitted from
human to human. The genomic sequence of MERS-CoV is closely
related to the sequences of certain bat coronaviruses (3–5), raising
concerns over persistent bat-to-human cross-species transmis-
sion of the virus. The clinical signs and epidemic patterns of
MERS-CoV are reminiscent of the severe acute respiratory syn-
drome coronavirus (SARS-CoV), the etiological agent of the
worldwide SARS epidemic in 2002-2003 that infected more than
8,000 people with a10% fatality rate (6, 7). MERS-CoV poses a
significant threat to global health and economy.
Coronaviruses are enveloped and positive-stranded RNA viruses
and can be divided into three major genera, , , and  (8). They
mainly cause respiratory, gastrointestinal, and central nervous system
diseases in mammals and birds. Coronaviruses recognize a variety of
host receptors. Human NL63 respiratory coronavirus (HCoV-NL63)
from -genus and SARS-CoV from -genus both recognize angio-
tensin-converting enzyme 2 (ACE2) as their host receptor (9, 10).
Porcine respiratory coronavirus (PRCV) and some other coronavi-
ruses from -genus recognize aminopeptidase N (APN) (11, 12).
Mouse hepatitis coronavirus (MHV) from-genus recognizes carci-
noembryonic antigen-related cell adhesion molecule 1 (CEACAM1)
(13, 14), although certain MHV strains also recognize heparan sulfate
(15, 16). Some coronaviruses from each of the three genera recognize
sugars (17–20). MERS-CoV belongs to the-genus and uses human
dipeptidyl peptidase 4 (DPP4) as its host receptor (21). Receptor rec-
ognition is a major determinant of coronavirus host range and tro-
pism.
An envelope-anchored trimeric spike protein is responsible for
coronavirus entry into host cells via binding to the host receptor
and subsequently fusing viral and host membranes (22). The spike
protein consists of a receptor-binding S1 subunit and a membrane
fusion S2 subunit. The S1 subunit contains two independent do-
mains, an N-terminal domain (NTD) and a C-domain, both of
which can potentially function as receptor-binding domains
(RBD) (Fig. 1A) (23). Specifically, coronavirus S1 C-domains can
function as ACE2-, APN-, or heparan sulfate-binding RBDs,
whereas S1 NTDs can function as CEACAM1- or sugar-binding
RBDs. To date, crystal structures have been determined for a
number of coronavirus RBDs by themselves or in complex with
their host receptors, revealing how coronaviruses have evolved to
recognize host receptors and thereby traffic between different spe-
cies (24–28). It is not known which one of MERS-CoV S1 domains
is the DPP4-binding RBD or how the tertiary structure of MERS-
CoV RBD fits into the landscape of coronavirus evolution.
Here we have identified the MERS-CoV S1 C-domain as the
RBD, characterized its interaction with human DPP4, and deter-
mined its crystal structure. This study provides structural insights
into the evolution and receptor recognition of MERS-CoV. The
identified MERS-CoV RBD also has therapeutic implications.
MATERIALS AND METHODS
Protein preparation and crystallization. The MERS-CoV S1 C-domain
(residues 367 to 588) was expressed and purified as previously described
for the SARS-CoV C-domain (24, 29, 30). Briefly, the MERS-CoV C-do-
main containing an N-terminal honeybee melittin signal peptide and a
C-terminal His6 tag was expressed in insect cells using the Bac-to-Bac
expression system (Invitrogen), secreted into cell culture medium, and
subsequently purified on a nickel-nitrilotriacetic acid (Ni-NTA) affinity
column and a Superdex 200 gel filtration column (GE Healthcare). The
protein was concentrated to 10 mg/ml and stored in buffer containing 20
mM Tris (pH 7.4) and 200 mM NaCl. Crystallization of the MERS-CoV
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C-domain was set up using the sitting drop vapor diffusion method, with
2 l protein solution added to 2 l reservoir buffer containing 27% (vol/
vol) polyethylene glycol (PEG) 3350, 0.2 M MgCl2, and 0.1 M bis-Tris (pH
7.0) at 20°C. After 2 weeks, crystals of the MERS-CoV C-domain were
harvested in buffer containing 25% (vol/vol) ethylene glycol, 27% (vol/
vol) PEG 3350, 0.2 M MgCl2, and 0.1 M bis-Tris (pH 7.0) and flash-frozen
in liquid nitrogen. Heavy-atom derivatives of MERS-CoV C-domain
crystals were prepared by soaking crystals for 15 min in buffer containing
1 M NaI, 25% (vol/vol) ethylene glycol, 27% (vol/vol) PEG 3350, 0.2 M
MgCl2, and 0.1 M bis-Tris (pH 7.0).
Data collection and structure determination. Data were collected at
the Advanced Photon Source beamline 24-ID-C at 1.0716 Å for native
crystals and 1.4586 Å for iodine-derivatized crystals. The crystal structure
was determined using SIRAS (single isomorphous replacement with
anomalous signal). X-ray diffraction data were processed using HKL2000
(31). Sixteen iodine sites were identified with the program HYSS (32)
followed by phase refinement and solvent flattening with RESOLVE (33).
The model was built and refined with Refmac (34) at 2.13 Å to a finalRwork
and Rfree of 14.9% and 20.6%, respectively. In the final model of the
MERS-CoV C-domain, 98% of residues are in the favored regions of the
Ramachandran plot, and 0% of residues are in the disallowed regions.
MERS-CoV infection assay. Vero cells were incubated with different
concentrations of recombinant MERS-CoV C-domain in minimum es-
sential medium (GIBCO) for 1 h at 37°C. Medium containing the protein
was removed, and the cells were infected with MERS-CoV at a multiplicity
of infection (MOI) of 0.01 for 1 h at 37°C. Unbound viruses were washed
with 1 phosphate-buffered saline (PBS), and the medium with MERS-
CoV C-domain was added back to the cells. Supernatant was sampled at
various time points, and the virus replication was determined by plaque
assays on Vero cells as described previously (35).
Pseudotyped-virus infection assay. Pseudotyped-virus infection was
carried out using murine leukemia viruses (MLVs) expressing -galacto-
sidase and pseudotyped with MERS-CoV spike protein as described pre-
viously (36). Briefly, to prepare pseudotyped viruses, HEK293T cells were
cotransfected with spike protein-encoding plasmid pcDNA3.1(),
p3240, expressing murine leukemia virus gag and pol genes, and a murine
leukemia virus -galactosidase-transducing vector, pBAG. At 48 h post-
transfection, virus supernatants were harvested and concentrated 20
times using Amicon Ultra-4 centrifugal filter units (Millipore) with 100-
kDa molecular mass cutoff. HEK293T cells transiently expressing human
DPP4 in pcDNA3.1() were inoculated in 96-well plates by adding 10 l
of concentrated viral supernatant to 100 l Dulbecco’s modified Eagle
medium (DMEM) per well. To examine the inhibition of MERS-CoV
C-domain on infection, HEK293T cells transiently expressing human
DPP4 were infected by pseudotyped virus in the presence of 20 g/ml
MERS-CoV C-domain or bovine serum albumin (BSA). Infection effi-
ciency was quantified 48 h postinfection by measuring -galactosidase
activity. As a negative control, HEK293T cells were transfected with empty
pcDNA3.1() plasmid, instead of a DPP4 insertion-containing plasmid.
As another control, MLVs pseudotyped with vesicular stomatitis virus
glycoprotein (VSV-G) were used to infect HEK293T cells transiently ex-
pressing human DPP4, in both the absence and presence of 20 g/ml
MERS-CoV C-domain protein or BSA.
DPP4 pulldown assay. HEK293T cells were transfected with either
empty pcDNA3.1() vector or pcDNA3.1() vector containing the hu-
man DPP4 gene. At 48 h posttransfection, cells were harvested and lysed in
PBS with 300 mM NaCl and 0.25% SDS. Cell lysate was mixed with
MERS-CoV C-domain. The protein complex was then precipitated with
Ni-NTA agarose (Thermo Scientific). DPP4 and MERS-CoV C-domain
contain a C-terminal hemagglutinin (HA) tag and His6 tag, respectively,
and were detected by anti-HA and anti-His6 antibodies (Santa Cruz Bio-
technology), respectively.
Protein structure accession number. Coordinates and structure fac-
tors have been submitted to the PDB, accession number 4L3N.
RESULTS AND DISCUSSION
Identification and functional characterization of MERS-CoV
RBD. We designed a construct of the MERS-CoV S1 C-domain
(residues 367 to 588), based on the sequence alignment of MERS-
CoV and SARS-CoV S1 subunits (Fig. 2A). Although the two S1
subunits have low sequence similarity, sequence alignment was
guided by conserved cysteines. Based on its crystal structure,
SARS-CoV C-domain contains eight essential cysteines that form
four disulfide bonds (24). Our designed MERS-CoV C-domain
also contains eight cysteines, seven of which are conserved be-
tween SARS-CoV and MERS-CoV (Fig. 2A). The MERS-CoV C-
domain was expressed and purified using the protocol that we
FIG 1 Crystal structure of the MERS-CoV S1 C-domain. (A) Domain structure of MERS-CoV S1 subunit that contains an N-terminal domain (NTD) and a
C-domain. The boundaries of the C-domain and proposed receptor-binding motif (RBM) of MERS-CoV were determined by sequence and structural com-
parisons with the SARS-CoV S1 subunit (see Fig. 2). (B) Sequence and secondary structure of the MERS-CoV C-domain. Helices are drawn as cylinders, and
strands are drawn as arrows. The disordered region is shown as a dashed line. (C) Crystal structure of the MERS-CoV C-domain. The core structure is in cyan,
and the proposed RBM region is in red.
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used for the SARS-CoV C-domain (24, 29, 30). The protein was a
monomer in solution, based on the gel filtration chromatography
profile.
We characterized the interactions between the recombinant
MERS-CoV C-domain and human DPP4 on human cell surfaces,
using three alternative approaches. First, the recombinant MERS-
CoV C-domain inhibits MERS-CoV infection of permissive mon-
key cells (Fig. 3A). The inhibition efficiency increased with the
concentration of MERS-CoV C-domain. At a 13 M concentra-
tion, the MERS-CoV C-domain completely inhibits MERS-CoV
infection. Second, the recombinant MERS-CoV C-domain inhib-
its the infection of MERS-CoV spike-pseudotyped retroviruses,
but not VSV-G-pseudotyped retroviruses, in cells that express hu-
man DPP4 (Fig. 3B). Finally, the MERS-CoV C-domain pulled
down human DPP4 from cells that express human DPP4 (Fig.
3C). These results all suggest that the recombinant MERS-CoV
C-domain interacts directly with cell surface human DPP4 and
competes with virus surface MERS-CoV spike protein for the
binding site on human DPP4. Therefore, we conclude that the
MERS-CoV S1 C-domain is the RBD that binds human DPP4.
Crystal structure of MERS-CoV RBD. Having identified the
MERS-CoV RBD, we further determined its crystal structure (Fig.
1B and C). The MERS-CoV RBD was crystallized in space group
P212121, with 2 molecules per asymmetric unit. The structure was
determined using an iodine derivative obtained by a short cryo-
soak (37) and refined at a 2.13-Å resolution (Table 1). The two
copies of MERS-CoV RBD occupying the same asymmetric unit
have a small buried interface (500 Å2), consistent with the ob-
servation during protein purification that the MERS-CoV RBD is
a monomer in solution.
The crystal structure of the MERS-CoV RBD contains a core
structure and an accessory subdomain (Fig. 1C). The core struc-
ture is a five-stranded antiparallel-sheet with several short-he-
lices. The accessory subdomain lies on one edge of the core struc-
ture and consists of a four-stranded antiparallel-sheet. The eight
cysteines in the RBD form four disulfide bonds (Fig. 2B). Three of
the disulfide bonds stabilize the core structure by connecting cys-
teine 383 to 407, 425 to 478, and 437 to 585; the remaining disul-
fide bond strengthens the accessory subdomain by connecting
cysteine 503 to 526. The RBD also contains 2 glycans that are
FIG 2 Sequence and structural comparisons of MERS-CoV and SARS-CoV S1 C-domains. (A) Sequence alignment of MERS-CoV and SARS-CoV C-domains.
Residues corresponding to C-domain core structures are in cyan, and residues corresponding to the proposed RBM region are in red. Cysteine residues are
highlighted. Asterisks indicate positions that have fully conserved residues; colons indicate positions that have strongly conserved residues; periods indicate
positions that have weakly conserved residues. (B) Crystal structure of MERS-CoV C-domain. The secondary structures are colored in the same way as the
corresponding sequence in panel A. Disulfide bond-linked cysteine residues are shown as sticks in yellow, and N-linked glycans are shown as sticks in green. (C)
Crystal structures of SARS-CoV C-domain (PDB 2AJF). Two disordered loops are drawn as dashed lines. Although cysteines 377 and 511 are disordered in this
structure, they were shown to form a disulfide bond in another study (46).
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N-linked to Asn410 in the core structure and Asn487 in the acces-
sory subdomain, respectively (Fig. 2B). We were able to trace all of
the RBD residues (except for the N-terminal 12 residues) with an
average B factor of 40.1 Å2. Overall, the MERS-CoV RBD has a
well-folded tertiary structure that is stabilized by disulfide bonds
and glycans.
Comparisons of MERS-CoV and SARS-CoV S1 C-domains.
The C-domains of -genus MERS-CoV and SARS-CoV (both
function as RBDs) have similar tertiary structures, despite their
low amino acid sequence similarity. The Z score between the two
RBDs is 11.9, as calculated by the protein folding Dali server (38).
Like the MERS-CoV RBD, the SARS-CoV RBD contains a core
structure and an accessory subdomain (Fig. 2C). The two core
structures are highly similar, both consisting of a five-stranded
antiparallel -sheet. The three disulfide bonds that strengthen the
core structure are all conserved between the two RBDs. On the
other hand, the accessory subdomains of the two RBDs are mark-
edly different. The accessory subdomain of the SARS-CoV RBD
mainly consists of loops, with a short two-stranded antiparallel
-sheet in the middle of the accessory subdomain. In contrast, the
same region in the MERS-CoV RBD mainly consists of a four-
stranded antiparallel -sheet. The disulfide bond that stabilizes
the accessory subdomain of MERS-CoV RBD is arranged differ-
ently in SARS-CoV RBD. Overall, the similar core structures of the
two RBDs suggest that the two RBDs share an evolutionary origin
and their different accessory subdomains resulted from divergent
evolution.
The accessory subdomain of -coronavirus S1 C-domains has
been shown to be a hypervariable region that -coronaviruses
often use for receptor recognition. This region in SARS-CoV C-
domain binds its receptor, ACE2, and thus has been named the
receptor-binding motif (RBM) (24). The same region in MHV
often contains long insertions or deletions, depending on the
MHV strain. In certain MHV strains, a six-amino-acid insertion
in this region allows the C-domain to recognize heparan sulfate
(15, 16). We propose that the accessory subdomain of MERS-CoV
C-domain also functions as RBM by binding to DPP4 and that
MERS-CoV and SARS-CoV have diverged in their RBMs to rec-
ognize different receptors (Fig. 4).
Why is the accessory subdomain in -coronavirus C-domain
hypervariable and often involved in receptor binding? The reason
is probably related to its location on the trimeric spike protein. As
TABLE 1 Data collection and refinement statistics
Parameter MERS-RBD nativea NaI derivativea
Data collection
Space group P212121 P212121
Cell dimensions
a, b, c (Å) 45.361, 108.065, 124.287 45.822, 108.817, 124.328
, ,  (°) 90, 90, 90 90, 90, 90
Resolution (Å) 50–2.13 (2.17–2.13) 50–2.32 (2.36–2.32)
Rsym or Rmerge 0.065 (0.459) 0.119 (0.574)
I/I 31.8 (2.0) 18.3 (2.0)
Completeness (%) 97.8 (62.3) 98.5 (90.5)
Redundancy 6.9 (4.3) 4.3 (2.7)
Refinement
Resolution (Å) 49.6–2.13
No. of reflections 34770
Rwork/Rfree 0.149/0.206









Bond lengths (Å) 0.008
Bond angles (°) 1.33
a Values in parentheses are for the highest-resolution shell.
FIG 3 Interactions between the MERS-CoV S1 C-domain and human DPP4.
(A) Dose-dependent inhibition of MERS-CoV infection by the MERS-CoV
C-domain. Vero cells were treated with increasing concentrations of the
MERS-CoV C-domain prior to infection. Virus titers were determined by
plaque assay and are shown as PFU/ml. (B) Inhibition of MERS-CoV spike-
pseudotyped retrovirus infection by MERS-CoV C-domain. MERS-CoV
spike-pseudotyped MLV and VSV-G-pseudotyped MLV were mixed with the
MERS-CoV C-domain and BSA, respectively. HEK293T cells transiently ex-
pressing human DPP4 were infected with different amount of pseudotyped
virus alone or its mixture with proteins. At 48 h postinfection, cells were lysed
and -galactosidase activities were measured. The -galactosidase activity of
cell lysate infected with 10 l pseudotyped virus alone was taken as 100%.
Values are means and standard errors of the means (SEM). (C) Pulldown of
cell surface DPP4 by MERS-CoV C-domain. 293T cells were transfected with
either empty vector or vector containing DPP4-HA gene. At 48 h posttrans-
fection, cells were harvested and lysed. Cell lysate was mixed with the MERS-
CoV C-domain containing a C-terminal His6 tag. The C-domain/DPP4 com-
plex was then precipitated with Ni-NTA beads.
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we have shown previously using electron microscopy, the S1 C-
domain is located on the membrane-distal tip of the trimeric spike
protein, with the accessory subdomain sitting on the very tip (39).
Hence, the accessory subdomain is the most exposed and protrud-
ing region on the whole spike protein, which has two results. First,
this region is exposed to the host immune system and thus evolves
at an increased pace to evade the host immune pressure. Second,
this region is easily accessible to potential host receptors. Conse-
quently,-coronaviruses can take advantage of the increased evo-
lution rate in this region to screen for and, if circumstances allow,
switch to new receptors.
Structural comparisonsofMERS-CoVand-coronavirus S1
C-domains. The C-domains of -genus MERS-CoV and -genus
HCoV-NL63 and PCRV (all function as RBDs) have different pri-
mary, secondary, and tertiary structures. Both HCoV-NL63 and
PCRV RBDs contain a -sandwich core structure consisting of
two -sheet layers that stack together through hydrophobic inter-
actions, which is significantly different from the core structure of
MERS-CoV RBD that consists of a single -sheet layer (Fig. 5).
The Z scores between MERS-CoV and HCoV-NL63 RBDs and
between MERS-CoV and PRCV RBDs are both less than zero,
suggesting no obvious similarity in their tertiary structures. Fur-
thermore, the proposed DPP4-binding RBM in MERS-CoV RBD
is also different from the ACE2-binding RBM in HCoV-NL63 and
the APN-binding RBM in PRCV (Fig. 4 and 5). The proposed
RBM in MERS-CoV RBD and the RBM in SARS-CoV RBD are
both single long and continuous subdomains, while the RBMs in
HCoV-NL63 and PRCV RBDs both consist of three short and
discontinuous loops. Despite their different tertiary structures,
these C-domains of - and -coronaviruses are located in the
same region of their S1 subunits, suggesting that they are evolu-
tionarily related.
A closer inspection of these coronavirus C-domains reveals
that the MERS-CoV RBD has a structural topology (connectivity
of secondary structural elements) related to those of -coronavi-
ruses, consistent with what we showed previously with the SARS-
CoV RBD (23). Although one of the -sheet layers in the RBD
core structure of -coronaviruses has become -helices in
-coronaviruses, all of the secondary structural elements in these
C-domains are connected in the same order (Fig. 5). These results
suggest that MERS-CoV and -coronavirus C-domains share an
evolutionary origin but have diverged dramatically to assume ter-
tiary structures with a similarity that is barely recognizable. The
evolutionary relationship between MERS-CoV and -coronavi-
rus C-domains may also be explained by the location of the C-do-
main on the tip of the trimeric spike protein and hence an in-
creased evolution rate of this domain.
Position of MERS-CoV S1 C-domains on landscape of coro-
navirus evolution. Here we summarize possible evolutionary re-
FIG 4 Comparison of receptor-binding mechanisms of coronavirus S1 C-do-
mains. These C-domains include HCoV-NL63 RBD complexed with human
ACE2 (PDB 3KBH), PRCV RBD complexed with porcine APN (4F5C), and
SARS-CoV RBD complexed with human ACE2 (2AJF). The arrow represents
interaction between the MERS-CoV RBD and human DPP4. RBMs and core
structures of coronavirus C-domains are in red and cyan, respectively, and
receptors are in green.
FIG 5 Comparison of tertiary structures of coronavirus S1 C-domains. (Top) Tertiary structures of coronavirus C-domains (PDB IDs are the same as in Fig. 4).
(Bottom) Schematic illustration of the structural topologies of coronavirus C-domains. -strands are depicted as arrows and -helices as cylinders. The
secondary structures of all of the coronavirus C-domains are colored and numbered in the same way as for the HCoV-NL63 C-domain.
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lationships between MERS-CoV and other coronavirus C-do-
mains (Fig. 6). All coronavirus C-domains likely share an
evolutionary origin because of their related structural topology.
They have diverged into the -sandwich core structure in -coro-
naviruses and the -sheet core structure in -coronaviruses. The
three RBM loops in -coronaviruses further diverged into
ACE2-binding RBMs in HCoV-NL63 and APN-binding RBMs
in PRCV. The RBM subdomain in -coronaviruses diverged into
ACE2-binding RBM in SARS-CoV, heparan sulfate-binding RBM
in some strains of MHV, and DPP4-binding RBM in MERS-CoV.
Therefore, this study has successfully positioned MERS-CoV RBD
on the landscape of coronavirus evolution and, during this pro-
cess, has also advanced our understanding of the evolution and
receptor recognition of coronaviruses.
Therapeutic implications. MERS-CoV RBD has therapeutic
implications. As we have shown in this study, MERS-CoV RBD
functions as an effective inhibitor of MERS-CoV entry (Fig. 3A).
In addition, MERS-CoV RBD is also a potential candidate for
MERS-CoV subunit vaccines. Previous studies have shown that
SARS-CoV RBD can elicit robust host immune responses against
SARS-CoV infections (40, 41). Likewise, the MERS-CoV RBD
identified in this study has a well-folded structure and interacts
strongly with human DPP4, making it a potential vaccine candi-
date. The determined structure of MERS-CoV RBD provides a
platform for structure-based design of effective MERS-CoV vac-
cines. For example, to help focus the antigenicity of the proposed
RBM region, new glycosylation sites may be introduced to the
surface of the core structure. In addition, to further stabilize
the RBD structure, new disulfide bonds can be introduced into
the RBD and some flexible loops can be modified. In sum, by
identifying the MERS-CoV RBD and determining its crystal struc-
ture, this study may be used to control the transmission of MERS-
CoV in humans.
ADDENDUM
During the submission and review of the present study, two other
studies independently mapped the MERS-CoV RBD fragments
(residues 358 to 588 and 377 to 662), both of which are similar to
the one identified in the present study (residues 367 to 588) (42,
43). These studies also showed that the RBD efficiently elicits neu-
tralizing antibodies, confirming that the crystal structure of
MERS-CoV can be useful in structure-based vaccine design.
In addition, two other studies independently determined the
crystal structure of MERS-CoV RBD (residues 367 to 606) com-
plexed with human DPP4 (44, 45). These studies delineated the
molecular interactions between the MERS-CoV RBD and its re-
ceptor and confirmed that the accessory subdomain in the MERS-
CoV RBD is the DPP4-binding RBM. The structures of the MERS-
CoV RBD as determined in these studies are a good match with the
structure reported in the present study (e.g., MERS-CoV RBD in
PDB 4KR0 can be superimposed onto the current structure with a
root mean square deviation [RMSD] of 0.82 Å). Although these
recently published studies are in general agreement with the pres-
ent study, this study is unique in that it focuses on (i) the evolution
of MERS-CoV and other coronavirus RBDs and (ii) the therapeu-
tic implications of MERS-CoV RBD. Both of these issues are crit-
ical for understanding and controlling MERS-CoV.
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